HealthKois, a healthcare-focused investment firm, has launched a new fund with a target corpus of $300 million, and an additional green shoe option of $100 million, it announced on Friday.
With the latest funding, HealthKois intends to target technology-enabled, scalable, and high-impact enterprises. Over the next four years, the firm will invest between $7 million to $25 million per company targeting early growth-stage businesses operating across healthtech, lifesciences, medtech, healthcare delivery and climate health, it said in a statement.
“HealthKois will back technology-led and innovative healthcare companies that address critical gaps in accessibility, affordability, and quality of care. Our goal is to transform care delivery by enabling early-growth ventures that bring real-world impact,” said Charles Janssen, Managing Partner, HealthKois. “With access to over 75% proprietary deal flow, we’re well-positioned to leverage our deep networks and operational expertise to deliver both superior financial returns and societal outcomes.”
HealthKois is a successor fund to HealthQuad I and II, which invested in Qure.AI, GoApptiv, and Cureskin, among others. The fund’s leadership team includes HealthQuad—Charles Janssen (Managing Partner), Ajay Mahipal (Partner), and Dr. Pinak Shrikhande (Partner).
“At HealthKois, we’re not just capital providers, we are long-term collaborators with founders, bringing strategic direction, global networks, and deep sector knowledge to help unlock their full potential. We invest in ventures that revolutionise healthcare delivery while also strengthening infrastructure resilience in India and other LMIC markets,” said Ajay Mahipal, Partner, HealthKois.
Last month, private equity firm Quadria Capital, which focuses on healthcare investments across South and Southeast Asia, closed its third fund with total commitments of $1.07 billion, significantly exceeding its $800 million target. PB Health, the healthcare venture of PB Fintech, has also raised $218 million led by General Catalyst.
